Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Why are tumour blood vessels abnormal and why is it important to know?

Open access
Nagy, J A, Chang, S-H, Dvorak, A M, Dvorak, H F · 2009 · British Journal of Cancer

Abstract

Tumour blood vessels differ from their normal counterparts for reasons that have received little attention. We report here that they are of at least six distinct types, we describe how each forms, and, looking forward, encourage the targeting of tumour vessel subsets that have lost their vascular endothelial growth factor-A (VEGF-A) dependency and so are likely unresponsive to anti-VEGF-A therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6604929

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic diagram of the angiogenic response induced by Ad-VEGF-A164. Modified from Pettersson et al (2000).
Figure 1 Schematic diagram of the angiogenic response induced by Ad-VEGF-A164. Modified from Pettersson et al (2000).CC BY · PubMed Central
Figure 2 Vascular patterns induced by Ad-VEGF-A164 (A, B) and by MOT, a mouse ovarian tumour (C). (A, B) FA and DV (black arrows) at 27 and 59 days after s.c. injection of 108 PFU of Ad-VEGF-A164. Most angiogenic vessels except for VMs (yellow arrows) have resolved. (C) Mouse ovarian tumour 10 days after s.c. implantation. Black arrows indicate some FA and DV; T, tumour.
Figure 2 Vascular patterns induced by Ad-VEGF-A164 (A, B) and by MOT, a mouse ovarian tumour (C). (A, B) FA and DV (black arrows) at 27 and 59 days after s.c. injection of 108 PFU of Ad-VEGF-A164. Most angiogenic vessels except for VMs (yellow arrows) have resolved. (C) Mouse ovarian tumour 10 days after s.c. implantation. Black arrows indicate some FA and DV; T, tumour.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 612

Metadata

Authors
Nagy, J. A., Chang, S.-H., Dvorak, A. M., & Dvorak, H. F.
Affiliations
Beth Israel Deaconess Medical Center (US)
Corresponding author
Dvorak, H F
Venue
British Journal of Cancer
Published
2009-02-24
Volume
100
Issue
6
Pages
865-869
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2063556542
Cited by
611
References
38
Citations by year
2026: 30 · 2025: 39 · 2024: 62 · 2023: 47 · 2022: 50 · 2021: 53 · 2020: 61 · 2019: 47 · 2018: 51 · 2017: 48 · 2016: 22 · 2015: 16 · 2014: 12 · 2013: 18 · 2012: 20
FWCI
1.38
Type
journal article
Language
en
Open access
Locations
  • British Journal of Cancer (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Foundation for Cancer Research
  • National Heart, Lung, and Blood Institute (R01HL064402, HL-64402)
  • National Cancer Institute (P01 CA 92644, P01CA092644)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
tumor vasculature, VEGF-A, anti-VEGF therapy, tumor angiogenesis, anti-angiogenic therapy resistance
MeSH terms
Animals, Blood Vessels, Capillaries, Humans, Neoplasms, Neovascularization, Pathologic, Vascular Endothelial Growth Factor A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Why are tumour blood vessels abnormal and why is it important to know? https://app.cochat.ai/papers/10.1038/sj.bjc.6604929
The paper
Nagy, J. A., Chang, S.-H., Dvorak, A. M., & Dvorak, H. F. (2009). Why are tumour blood vessels abnormal and why is it important to know? British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6604929

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.